Product Description: Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8./[2]Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571./[3]Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074.
CAS Number: 1372645-37-8
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
